Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
PBS Top Five
Pain & addiction: a growing market
Pfizer's Lyrica is driving growth in a market that has lately seen the emergence of new drugs and new players although the industry giant is dominant.
Pipeline Monitor
PCSK9 inhibitors push ahead
Praluent and Keytruda hot on the heels of rivals, first malaria vaccine and new ADHD drug.
Working Life
Public speaking, how to beat the fear
Public speaking has a bad reputation. The oft-quoted statistic is that around three-quarters of people fear it more than anything else but presentation skills are now considered vital to advancing your career, so overcoming the fear is key.
Approvals Action
First threat to $60m Velcade
Potential generic competition for Janssen's cancer treatment Velcade, worth close to $60 million a year in PBS earnings, has appeared on the drugs register.
Special Report
What next for regulation
The report into medicines regulation has been released, to a largely positive response, but with stakeholder forums taking place next week, industry is waiting to see what will be adopted.
Open Forum
Crestor case to set new threshold
When the High Court hands down its decision in the Crestor case, it is expected to clarify assessment of the obviousness of a method of treatment, write Rebecca Currey and Jane Owen of law firm Bird & Bird.